Giving immunotherapy earlier in the day can significantly extend patients' survival, compared to giving treatment later in the day, a new study of lung cancer shows.

High levels of IB6 are often found in NSCLC, making it a good target for treatment. A preclinical study found that in lung cancer, IB6 was correlated with interleukin-8 levels and promoted cancer cell ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in ...

Ask a clinical question and tap into Healio AI's knowledge base. Lung cancer is generally the top cause of cancer-related death globally and in the United States (US). In the US in 2023, lung cancer ...

A team of doctors and researchers have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked. A team of doctors and researchers at Memorial ...